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ABSTRACT 
The irritative effects of preservatives found in ophthalmologic solution, or of antiseptics used for skin disinfec-
tion is a consistent problem for the patients. The reduction of the toxic effects of these compounds is desired. 
Brilliant Blue G (BBG) has shown to meet the expected effect in presence of benzalkonium chloride (BAK), a 
well known preservative in ophthalmic solutions, and octenidine dihydrochloride (Oct), used as antiseptic in skin 
and wound disinfection. BBG shows a significant protective effect on human corneal epithelial (HCE) cells 
against BAK and Oct toxicity, increasing the cell survival up to 51 % at the highest BAK or Oct concentration 
tested, which is 0.01 %, both at 30 min incubation. Although BBG is described as a P2x7 receptor antagonist, 
other selective P2x7 receptor antagonists, OxATP (adenosine 5’-triphosphate-2’,3’-dialdehyde) and DPPH (N’-
(3,5-dichloropyridin-4-yl)-3-phenylpropanehydrazide), did not reduce the cytotoxicity of neither BAK nor Oct. 
Therefore we assume that the protective effect of BBG is not due to its action on the P2x7 receptor. Brilliant 
Blue R (BBR), a dye similar to BBG, was also tested for protective effect on BAK and Oct toxicity. In presence 
of BAK no significant protective effect was observed. Instead, with Oct a comparable protective effect was seen 
with that of BBG. To assure that the bacteriostatic effect is not affected by the combinations of BAK/BBG, 
Oct/BBG and Oct/BBR, bacterial growth inhibition was analyzed on different Gram-negative and Gram-positive 
bacteria. All combinations of BAK or Oct with BBG hinder growth of Gram-positive bacteria. The combinations 
of 0.001 % Oct and BBR above 0.025 % do not hinder the growth of B. subtilis. For Gram-negative bacteria, 
BBG and BBR reduce, but do not abolish, the antimicrobial effect of BAK nor of Oct. In conclusion, the addi-
tion of BBG at bacterial inhibitory concentrations is suggested in the ready-to-use ophthalmic preparations and 
antiseptic solutions. 
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INTRODUCTION 
Brilliant Blue G (BBG) is widely used as 
a dye for proteins in gel electrophoresis. Its 
power to stain proteins has led to its applica-
tion in vitreoretinal surgery for the staining 
of the internal limiting membrane (ILM), as 
it showed no toxic effects at the clinically 
suggested concentration, 0.025 %, while 
showing good staining ability (Enaida et al., 
2006). Later, BBG was found to be a great 
asset also in the treatment of the spinal cord 
injury, because it reduced the local inflam-
matory responses, showed protective effects 
towards the spinal cord neurons and im-
proved the motor recovery (Marcillo et al., 
2012; Peng et al., 2009). The authors paired 
the physiological function of BBG with its 
activity as a P2x7 receptor antagonist as the 
spinal cord neurons express this receptor 
abundantly at their surface.  
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In previous studies, we showed that BBG 
protects ARPE retinal pigment epithelium 
cells against the toxicity of trypan blue (TB), 
which is another widely used dye for the 
staining of the ILM in eye surgery (Awad et 
al., 2013). This observation was unexpected, 
and no clear mechanism was proposed. Also, 
it was not known whether the protective ef-
fect of BBG was limited to TB, or whether it 
was more universal. Brilliant Blue R (BBR) 
is a dye very similar to BBG, which differs 
only by the absence of two methyl groups. 
BBR, in contrast to BBG, has never been 
used medically. In the literature, BBR is 
used only as a sensitive protein stain in poly-
acrylamide gel electrophoresis (Servaites et 
al., 2012). In this study we have tested the 
cytotoxicity of benzalkonium chloride 
(BAK) and octenidine (Oct) in combination 
with BBG or BBR in order to see whether 
there is any significant reduction in the tox-
icity of the compounds on human corneal ep-
ithelial cells (HCE). BAK is a widely used 
preservative in ophthalmic drops, even 
though it is known to have cytotoxic effects 
and causes easily inflammation in the eye 
surface (Ammar and Kahook, 2011; Dutot et 
al., 2006; Liang et al., 2012; Paimela et al., 
2012). Oct is an antiseptic agent for skin, 
mucous membranes and wounds, and is used 
in many preparations as a replacement for 
other antiseptics, because it shows a signifi-
cantly higher efficiency already at very low 
concentrations (Hübner et al., 2010; 
Koburger et al., 2010). At the clinically and 
industrially used concentrations, both com-
pounds show high cytotoxicity against 
mammalian cells. After only 5 minutes incu-
bation with HCE cells, less than 20 % of the 
cells were found to be metabolically active. 
Interestingly, we found a high protective ef-
fect of BBG against the cytotoxic action of 
BAK and Oct, without an excessive reduc-
tion of the bacteriostatic effect.  
 
MATERIALS AND METHODS 
Materials 
Dulbecco’s Modified Eagles Medium 
with Ham’s F12 (DMEM + F12), BAK, 
BBG, BBR, OxATP (adenosine 5’-triphos-
phate-2’,3’-dialdehyde) were purchased from 
Sigma-Aldrich (Schnelldorf, Germany). Oct 
was provided by Schülke & Mayr GmbH 
(Norderstedt, Germany). HCE cells were 
from Riken Bioresource Center (Tsukuba, 
Japan). WST-1 cell proliferation reagent was 
from Roche Diagnostics (Mannheim, Ger-
many). Fetal bovine serum (FBS) and peni-
cillin/streptomycin (Pen/Strep) were from 
Biochrom (Germany). Human epithelial 
growth factor (hEGF), insulin, amphotericin 
B, and L-glutamine were from Sigma-
Aldrich (Steinheim, Germany), TrypLE Ex-
press was from Gibco (USA). DPPH (N’-
(3,5-dichloropyridin-4-yl)-3-phenylpropane-
hydrazide) was synthesized as described by 
Lee et al. (2012). The medium MHB 
(Mueller-Hinton Bouillon) was from Carl 
Roth (Germany). 
 
Test solutions 
BBG was used between 0.0025 and 
0.075 %, in combination with either BAK 
between 0.001 and 0.01 %, or Oct between 
0.002 and 0.01 %. BBR was tested between 
0.0025 and 0.05 % in the presence of BAK 
at 0.004 % and Oct at 0.003 %. As negative 
control PBS was used. Each of these concen-
trations were tested also alone on HCE cells 
as well as on the below mentioned bacterial 
strains. 
 
Cell culture and cell viability assay 
HCE cells were cultivated in DMEM + 
F12 media, supplemented with 15 % FBS, 
1 % Pen/Strep, 25 μg/ml amphotericin B, 
5 μg/ml insulin, 10 ng/ml hEGF and 2 mM 
L-glutamine, at 37°C and 5 % CO2. The cells 
were passaged by trypsinization with Try-
pLE Express and seeded at a density of 
20,000 cells/well in a 96 well, flat bottom 
plate and grown for 48 h prior to experiment. 
After the cells reached confluence, they were 
incubated with 50 μl/well of different test so-
lutions for 5, 30 and 60 min at 37 °C and 
then washed 3 times with PBS (w/o Ca2+ and 
Mg2+). One hundred μl of diluted WST-1 cell 
proliferation reagent (diluted 1:4 in PBS, 
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then 1:10 in cell culture medium) was added 
to each well and incubated with the cells at 
37 °C for 4 h. The WST-1 reagent, which is 
a tetrazolium salt, is reduced to a red forma-
zan dye by the mitochondrial dehydrogenas-
es of metabolically active cells. We had 
checked previously that the readings for this 
dye are not influenced by any remaining 
BBG (Awad et al., 2013). The amount of 
formazan dye formed was taken as a measure 
of cell survival. The absorbance of the plate 
was measured in an MR5000 plate reader 
(Dynatech) at 450 nm. All test solutions 
were tested in three independent experi-
ments, with 6 to 12 measurements for each 
experiment. 
 
Determination of inhibitory concentrations 
for bacterial cells 
The Gram-positive bacteria Bacillus sub-
tilis, Clavibacter michiganensis and Paeni-
bacillus sp. as well as the Gram-negative 
bacteria Escherichia coli DH5α, Pseudomo-
nas putida DSM 291 and Vibrio sp. Gal12 
were used in the assay. The antimicrobial ac-
tivities of the compound mixtures were as-
sayed in micro-titer plates. For this, 100 µl of 
MHB were aliquoted into each well of the 
micro-titer plate, followed by 20 µl of a mix-
ture of antimicrobial compounds and 100 µl 
of the bacterial suspension (approximately 
2·106 cells/ml). Deionized water was used as 
negative control. All micro-titer plates were 
incubated overnight at 28 °C, except for E. 
coli plates, which were incubated at 37 °C. 
Following overnight incubation, the plates 
were examined for visible bacterial growth 
evidenced by the turbidity. Where no turbidi-
ty was seen, we assumed that there is no bac-
terial growth. For each compound, the assay 
was performed in triplicate in three inde-
pendent experiments and in accordance with 
Jorgensen and Turnidge (2007).  
 
RESULTS 
To investigate the influence of the time 
and the concentrations of BBG, BAK and 
Oct on the HCE cell viability, as well as their 
impact on the bacterial growth inhibition, the 
cells were exposed to different concentra-
tions of these compounds. Our results 
showed that BAK was highly toxic for HCE 
cells. Already in concentrations of 0.001 % 
and 5 min incubation, 30 % cell loss was ob-
served. For longer exposure, as would be 
used in wound treatment, concentrations of 
0.002 % reduced the cell survival to 20 % or 
less. The inclusion of BBG, in the concentra-
tion of 0.025 % used clinically for staining 
procedures, reduced the toxicity of BAK 
considerably (Figure 1). This protective ef-
fect of BBG led to an increase of cell surviv-
al, with 50 % at 5 min, with 35 % at 30 min 
and with 27 % at 60 min incubation at a con-
centration of BAK 0.01 %, the highest con-
centration tested in this study.  
The cell survival after exposure to BAK 
in the presence of different BBG concentra-
tions is shown in Figure 2. Even at low BBG 
concentrations, the compound showed sig-
nificant increase of the cell survival: at 
0.007 % BBG, 67 % of the cells survived 
exposure to 0.004 % BAK, and 48 % sur-
vived when exposed to 0.006 % BAK. With-
out BBG, cell survival at these concentra-
tions of BAK was around 15 % (Figure 1). 
At higher BAK concentrations, higher BBG 
concentrations have to be chosen; for exam-
ple at 0.01 % BAK with 0.015 % BBG the 
cell survival increased to 37 % and with 
0.030 % BBG to 46 %, at 30 min incubation, 
whereas in the absence of BBG, cell survival 
of only a few percent was seen. 
Oct is an antiseptic agent which, in com-
parison with BAK, had a higher bacteriostat-
ic effect, but at the same time was more toxic 
to the cells, as shown in Figure 3a. BBG pro-
tected the cells against Oct toxicity even 
more than against BAK toxicity. After 5 min 
incubation with 0.009 % Oct and 0.025 % 
BBG, the cell survival increased to 95 %, 
and after 30 min incubation, to 85 %, while 
in the absence of BBG, Oct led to almost 
complete cell death. In order to find the best 
combination between Oct and BBG, differ-
ent concentrations of BBG and Oct were 
tested in mixture for 30 min incubation (Fig-
ure 3b). For 0.003 % Oct, already 0.007 % 
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BBG abolished the toxicity of the antiseptic. 
For 0.007 % Oct, a higher concentration of 
BBG, namely 0.025 %, had to be taken, in 
order to achieve the same effect. At 0.01 % 
Oct concentration, the minimal concentration 
of BBG needed is 0.025 %, and the cell sur-
vival increased to 95 %.  
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Figure 1: Survival of HCE cells after exposure 
for 5, 30 and 60 minutes to different concentra-
tions of BAK in PBS (“BAK alone”) and in combi-
nation with 0.025 % BBG . The error bars repre-
sent the standard deviations of 6 to 12 replicates 
performed within the same experiment. 
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Figure 2: Cell survival of HCE cells after expo-
sure for 30 min to combinations of BAK and BBG 
in different concentrations . 
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Figure 3: Cell survival of HCE cells after expo-
sure for 5 and 30 min to different concentrations 
of Oct with and without 0.025 % BBG (a) and af-
ter exposure for 30 min to different combinations 
of BBG and Oct (b). The error bars represent the 
standard deviations of 6 to 12 replicates per-
formed within the same experiment. 
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BBR is a dye which differs from BBG 
only by the absence of two methyl groups. 
This difference changed significantly the 
protective activity of BBR against BAK and 
only slightly against Oct. At 0.004 % of 
BAK there was no considerable cell survival 
in presence of BBR at 0.025 % or higher, 
while with BBG, the cell survival increased 
up to 74 % (Figure 4a). The highest protec-
tive effect of BBR was obtained at 0.0075 %, 
where the HCE cell survival increased to 
52 %. This was considerably less than the 
protective effect of BBG at the same concen-
tration, which was 83 %. At 0.003 % of Oct 
BBR showed comparable protective effect 
with that of BBG (Figure 4b). The highest 
cell survivals at this Oct concentration was 
found at 0.015 % and 0.025 % BBR concen-
trations, which was 102 % and 90 %, respec-
tively. While with BBG at the same concen-
trations the cell survival was 115 % and 
100 %, respectively. Above 0.05 % of BBR 
or BBG, in presence of Oct, the HCE cells 
showed a considerable decrease in cell sur-
vival. 
To determine if the protective effect of 
BBG on antiseptics was due to its P2x7 re-
ceptor antagonist activity, other reported se-
lective P2x7 receptor antagonist were tested 
in this study. One of them was OxATP. It is 
known as an irreversible P2x7 receptor an-
tagonist, which blocks human P2x7 receptors 
at 10 μM concentration (Hibell et al., 2001; 
Wang et al., 2004). The other antagonist was 
DPPH, recently synthesized by Lee et al. 
(2012), which has an IC50 of 0.65 μM with 
ethidium bromide uptake assay. Neither Ox-
ATP, used between 2 μM and 2mM (prein-
cubated for 30 min with HCE cells prior to 
exposure to BAK), nor DPPH, used between 
0.1 μM and 10 μM, showed any protective 
effect against BAK toxicity, when BAK is 
present between 0.001 and 0.01 %. Oct was 
tested between 0.003 % and 0.01 % only in 
presence of DPPH and no protective effect of 
the P2x7 receptor antagonist was found (data 
not shown) 
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Figure 4: Cell survival of HCE cells after expo-
sure for 30 min to BBR or BBG, in the presence 
of 0.004 % BAK (a) or 0.003 % Oct (b). The error 
bars represent the standard deviations of 6 to 12 
replicates performed within the same experi-
ment. 
 
Bacteriostatic effect of Oct and BAK in the 
presence of BBG and BBR 
Mixtures of BAK or Oct with BBG and 
BAK or Oct with BBR were used to deter-
mine the susceptibility of diverse bacterial 
strains towards the compound combinations. 
The BAK and Oct at concentrations between 
0.002 % and 0.01 % inhibited the growth of 
all tested Gram-positive bacterial strains, 
even when mixed with the highest applied 
BBG concentration. In general, Gram-
positive bacteria were more susceptible to-
wards the compounds than Gram-negative 
bacteria. The inhibitory concentrations for 
Gram-negative bacterial growth were sum-
marized in Figure 5 and Figure 6. All tested 
Gram-negative bacteria showed similar re-
sponses towards Oct and BAK when the 
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Figure 5: Concentrations of BAK and Oct requi-
red to inhibit Gram-negative bacterial growth, 
when BBG is present. At combinations within the 
shaded area bacterial growth is observed; com-
binations above the shaded areas prevent bacte-
rial growth. 
 
same concentration of BBG was used. These 
results suggested that the growth of different 
bacterial organisms were efficiently inhibited 
by the use of 0.015 % BBG with 0.009 % 
BAK or 0.007 % Oct, as well as by the use 
of 0.007 % BBG with 0.005 % BAK or 
0.003 % Oct.  
BBR was assayed in combination with 
Oct on the Gram-negative and Gram-positive 
bacterial strains used before, to test whether 
BBR has the same bacterial inhibitory effect 
as BBG. The results showed that the bacteri-
al growth of the Gram-positive bacterium, B. 
subtilis was not inhibited in presence of high 
BBR concentrations, i.e. 0.025 % or 0.030 % 
combined with 0.001 % Oct there. For the 
Gram-negative bacteria, increasing Oct con-
centrations were required with increasing 
BBR concentrations, similar to BBG (see 
Figure 6). The results showed that the 
growth of all tested bacterial strains were in-
hibited by the use of 0.007 % BBR with 
0.005 % of Oct, 0.012 % BBR with 0.007 % 
Oct and 0.020 % BBR with 0.009 % Oct. 
Combinations between BBR and BAK have 
not been investigated, because no significant 
protective activity of BBR on human cell 
lines was seen in presence of BAK. 
The concentrations of BAK used in this 
study are in the range of concentrations used 
in the commercially available eye drops, 
0.004-0.02 % (Liang et al., 2012), where 
0.025 % BBG exerted a significant cell via-
bility increase on HCE cells. To achieve bac-
terial growth inhibition, as well as a signifi-
cant increase of the cell viability, higher 
concentrations of BBG required higher BAK 
concentrations. The best combinations be-
tween these two compounds were 0.015 % 
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Figure 6: Concentrations of BAK and Oct re-
quired to inhibit Gram-negative bacterial growth, 
when BBR is present. At combinations within the 
shaded area bacterial growth is observed; com-
binations above the shaded areas prevent bacte-
rial growth. 
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BBG for BAK between 0.008 % and 0.01 %, 
and 0.007 % BBG for BAK between 
0.004 % and 0.006 %. The HCE cell viabil-
ity increased between 40-60 % in the first set 
of combinations between BBG and BAK, 
and with 50-80 % in the second case. 
Oct was used in this study between 
0.002 % and 0.01 %, because according to 
Hübner et al., (2010) 22.5 mg/l of OPE (Oct 
with phenoxyethanol) was sufficient to re-
duce with 3log10 the bacterial growth after 
30 min incubation. At these concentrations 
of Oct, 0.025 % BBG increased the HCE cell 
survival with up to 100 % at 30 min incuba-
tion. Also BBR at the same concentration 
and incubation time increased the HCE cell 
survival up to 90 %, when 0.003 % Oct was 
present. To reduce the toxicity of the antisep-
tic agent, without affecting the bacterial in-
hibitory effect, we suggest the following 
combinations: 0.025 % of BBG with 0.01 % 
Oct; 0.015 % BBG with 0.007 % Oct; and 
0.007 % BBG with 0.003 % Oct. With these 
combinations, the HCE cell survival in-
creased with 35-115 %. 
 
DISCUSSION 
The inflammatory responses of the eyes 
or skin due to the repeated contact with pre-
servatives and antiseptics used in different 
eye drops, wound disinfectants or cosmetical 
products, are unwanted side effects, and are 
present in many patients using these products 
on a daily basis. The reason for these in-
flammatory effects is the high toxicity of the 
compounds on the target cells. Therefore, re-
ducing the toxicity of antiseptics and pre-
servatives on human tissues, while maintain-
ing their bacteriostatic effect, is desired. 
Ways to reduce these inflammatory effects, 
by combination of bacteriostatic agents with 
protective agents, were not yet investigated. 
We found that the protective effect of 
BBG against BAK and Oct toxicity on hu-
man eye cells is remarkable. However, there 
are only limited numbers of possible combi-
nations between different concentrations of 
BBG and BAK or Oct, at which the bacterial 
growth is inhibited. Very high concentrations 
of BBG, 0.03 % or higher, in presence of ei-
ther of the two antiseptics, at the tested con-
centrations, does no longer inhibit the bacte-
rial growth of Gram-negative bacteria. BBR 
showed protective effect only against Oct 
toxicity, however this effect is little lower 
than the one caused by BBG. 
The microbiology experiments showed 
that the mixtures between BAK with BBG, 
Oct with BBG and Oct with BBR had 
stronger inhibitory effects against Gram-
positive than against Gram-negative bacterial 
cells. Since the cell wall composition in both 
groups of bacteria differs remarkably 
(Silhavy et al., 2010), the hydrophobic outer 
membrane of Gram-negative bacteria poten-
tially might prevent the compounds to effi-
ciently enter the cells. However, hydrophilic 
features of the compounds might aid the en-
trance of the antimicrobials into Gram-
positive cells thus making them more sus-
ceptible. Previously McDonnell and Russell 
(1999) and Fazlara and Ekhtelat (2012) re-
ported that BAK is more effective on Gram-
positive bacterial organisms. They also men-
tioned that the mechanism of action of BAK, 
as a cationic quaternary ammonium com-
pound, is based on the interaction of the neg-
atively charged bacterial surface with the 
positively charged headgroup of BAK. After 
the binding on the bacterial surface, BAK 
will enter the cell wall and cause its disrup-
tion and leakage of the cytoplasmic material 
to the outside. The mechanism of action of 
Oct has not been described yet, but we as-
sume that it is similar to BAK. Both of them 
have an amphiphilic structure, but Oct is a 
more complex molecule, with two cationic 
centers and long hydrophobic chains at both 
ends of the molecule. Oct and BAK had pre-
viously been successfully tested as antimi-
crobial compounds (Hübner et al., 2010; 
Sedlock and Bailey, 1985). In comparison 
with BAK, Oct showed a higher efficiency 
against Gram-negative bacteria.  
We have demonstrated here that BBG 
reduces the antibacterial effect of Oct and 
BAK for Gram-negative bacteria. Neverthe-
less, the use of certain concentration combi-
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nations of the compounds, presented in Fig-
ure 5, will efficiently inhibit the growth of 
bacteria in eye drops, skin, mucous mem-
branes and wounds disinfectants, while pro-
tecting the epithelial cells against the cyto-
toxic action of the disinfectants. BBR reduc-
es the growth of gram-negative bacteria less 
efficiently than BBG at any of the tested 
concentrations, when mixed with Oct.  
Recently, Müller and Kramer (2008) de-
fined the biocompatibility index (BI) of anti-
septic compounds. They measured the IC50 
value of the antiseptics on fibroblast cells 
and divided this value with the concentration 
at which 99.9 % of the Gram-positive and 
Gram-negative bacteria are killed. A BI big-
ger than 1 would mean that an antiseptic 
compound is more toxic to the bacterial or-
ganisms in comparison with the mammalian 
cells. In order to quantify, in our case, the ef-
fectiveness of the different concentration 
combinations between BBG and Oct or BAK 
in antiseptic treatments, a similar BI of the 
two antiseptic compounds in the presence of 
BBG will be defined as the next step of this 
study. 
Previously Dutot et al. (2006) reported 
that BAK induces apoptosis in corneal and 
conjunctival cell lines through the activation 
of the P2x7 receptor. The activation of this 
receptor leads to pore formation and influx 
of Ca2+ and other extracellular molecules in-
to the cell, but also to the escape of intracel-
lular small metabolites (Chung et al., 2000; 
Dutot et al., 2006; Wang et al., 2004). The 
exact mechanism of the protective activity of 
BBG and BBR is not yet known. We as-
sume, however, that it does not involve the 
P2x7 receptor, because other selective P2x7 
receptor antagonists, OxATP and DPPH, did 
not show any protection against the cytotoxic 
effect of these antiseptics. Recently Jo and 
Bean (2011) showed that BBG at micromo-
lar concentrations also causes inhibition of 
neuronal voltage gated sodium channels in 
neuroblastoma cells. The binding constants 
to these channels are far higher than those of 
the classic sodium channel blockers used in 
medical treatments of traumatic brain injury 
(Pitkanen et al., 2014). Further investigations 
are needed to elucidate on which target BBG 
and BBR acts when inhibiting the toxicity of 
BAK or Oct on HCE cells. BBR, in contrast 
to BBG, was less studied in the past. This 
dye is often used in literature as a stain for 
detection of proteins in polyacrylamide gel 
electrophoresis. No protective effect of the 
dye on human cells has been described yet, 
nor any activity on any cellular receptors. 
The chemical interaction between nega-
tively charged dye molecules and antiseptics, 
which have one (BAK) or two (Oct) positive 
charges, could be one reason, why BBG and 
BBR reduces the toxicity of Oct or BAK on 
HCE cells. This idea is supported also by our 
data, where certain mixtures between the 
dyes and the antiseptics reduce the bacterio-
static effect of the antiseptics on Gram-
negative bacteria. This interaction could re-
sult in a compound that is not anymore toxic 
to neither the mammalian cells nor to the 
Gram-negative bacteria. Interestingly, the 
bacteriostatic effect of the dye-preservative 
mixtures on Gram-positive bacteria is not af-
fected by these interactions. In the literature 
it is mentioned that BBR, during the protein 
staining procedure, binds reversibly and es-
pecially to positively charged parts of the 
proteins (Tal et al., 1985), with a slightly dif-
ferent molecular mechanism than BBG (Lee 
et al., 2001). Casero et al. (1997) described 
studies of the interaction of the negatively 
charged BBG with several types of cationic 
surfactants and the formation of dye-
detergent premicellar aggregates at surfac-
tant concentrations far below their critical 
micelle concentration. Ma et al. (2014) 
showed that BAK is able to interact with 
other negatively charged dye molecules, eo-
sin Y and eosin B and form stable dye-
surfactant aggregates. Also Sütterlin et al. 
(2008) presented studies where other nega-
tively charged molecules, such as linear al-
kylbenzene sulfonate, naphthalene sulfonic 
acid, benzene sulfonic acid or SDS, can con-
siderably modify the bacteriostatic effect of 
BAK on two Gram-negative bacterial strains, 
P. putida and V. fischeri.  
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There are several preparations with BAK 
or Oct as an antiseptic already available on 
the market. The combinations between Oct 
and BBG or BBR, or BAK and BBG, pro-
posed by us in this study, will help in mark-
ing the disinfected area and in protecting the 
skin from possible irritations or inflamma-
tions caused by the antiseptics. The protec-
tive effect of BBG and BBR will also allow 
to use higher concentrations of the antisep-
tics in the ready-to-use preparations. Howev-
er, the daily use of BBG based solutions on 
skin or in eyes will have as a side effect the 
staining of the surface in blue, where the 
treatment is applied, but according to Peng et 
al. (2009) and our own experience, the stain-
ing disappears rapidly, and is gone about a 
week after the treatment. With BBR no such 
effect has been described yet in the literature, 
but we assume that it has a similar staining 
effect with BBG, because BBR is widely 
used as a high sensitivity protein stain. 
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